Our findings indicate that Axl inhibitor, TP-0903 was active at inducing in vitro apoptosis in CLL B-cells from relapsed patients placed on ibrutinib therapy and also was highly effective against CLL B-cells from two patients who had progressed while on ibrutinib treatment. Here, AXL is linked to B-cell chronic lymphocytic leukemia.